1. Azzedine H, Senderek J, Rivolta C, Chrast R. Molecular genetics of charcot-marie-tooth disease: from genes to genomes. Mol Syndromol 2012; 3:204-214.
2. Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet 2015; 8:235-243.
3. Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. Eur J Hum Genet 2009; 17:703-710.
4. Verma A. Next-generation sequencing and genetic diagnosis of Charcot-Marie-Tooth disease. Ann Indian Acad Neurol 2014; 17:383-386.
5. Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot–Marie–Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet 2015; 8:235-43.
6. van Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. Orphanet J Rare Dis 2014; 19: 9-38.
7. Brennan KM, Bai Y, Pisciotta C, Wang S, Feely SM, Hoegger M, et al. Absence of Dystrophin Related Protein-2 disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease. Neuromuscul Disord 2015; 25:786-793.
8. Çağlayan AO. Clinical utility of next-generation sequencing in neurodevelopmental disorders: non-syndromic intellectual disability as a model. FNG & Bilim Tıp Dergisi 2015;1:52-57.
9. Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. Exome sequencing: current and future perspectives. G3 (Bethesda) 2015; 5:1543-1550.
10. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet 2012; 91:597-607.
11. Jani-Acsadi A, Krajewski K, Shy ME, editors. Charcot-Marie-Tooth neuropathies: diagnosis and management. Semin Neurol.; 2008: 28:185-194.
12. Fabrizi GM, Cavallaro T, Angiari C, Cabrini I, Taioli F, Malerba G, et al. Charcot–Marie–Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2006; 130:394-403.
13. Rezende RL, Bonjardim LR, Neves EL, Santos LC, Nunes PS, Garcez CA, Souza CC, Araújo AA. Oral health, temporomandibular disorder, and masticatory performance in patients with charcot-marie-tooth type 2. Scientific World Journal 2013; 2013:425651.
14. Karol LA, Elerson E. Scoliosis in patients with Charcot-Marie-Tooth disease. JBJS 2007; 89:1504-1510.
15. Bamford NS, White KK, Robinett SA, Otto RK, Gospe Jr SM. Neuromuscular hip dysplasia in Charcot–Marie–Tooth disease type 1A. DMCN 009; 51:408-411.
16. Roberts RG, Freeman TC, Kendall E, Vetrie DL, Dixon AK, Shaw-Smith C, et al. Characterization of DRP2, a novel human dystrophin homologue. Nat Genet 1996; 13:223-226.
17. Roberts RG, Sheng M. Association of Dystrophin-Related Protein 2 (DRP2) with Postsynaptic Densities in Rat Brain. Mol Cell Neurosci 2000; 16:674-685.
18. Gee SH, Madhavan R, Levinson SR, Caldwell JH, Sealock R, Froehner SC. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J Neurosci 1998; 18:128-137.
19. Šedivá A, Smith CE, Asplund AC, Hadač J, Janda A, Zeman J, et al. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol 2007; 27:640-646.
20. Toma C, Torrico B, Hervás A, Valdés-Mas R, Tristán-Noguero A, Padillo V, et al. Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. Mol Psychiatry 2014; 19:784-790.